UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000003283 |
|---|---|
| Receipt number | R000003873 |
| Scientific Title | A randomized study of Docetaxel + Cyclophosphamide (TC), 5-fluorouracil + Epirubicin + Cyclophosphamide (FEC)-TC and TC-FEC as preoperative chemotherapy for hormone receptor positive and HER2 negative primary breast cancer JBCRG-09 |
| Date of disclosure of the study information | 2010/03/03 |
| Last modified on | 2021/08/18 10:12:32 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2010/03/02 23:21:13 | ||
| 2 | Update | 2010/03/03 11:28:09 | Date of disclosure of the study information |
|
| 3 | Update | 2011/11/28 15:52:40 | Last follow-up date |
|
| 4 | Update | 2012/05/16 13:50:16 | Post marketing survey by drug manufacture etc., specified by Japanese law. Institutions |
|
| 5 | Update | 2012/09/02 17:54:17 | Recruitment status |
|
| 6 | Update | 2014/10/02 09:58:24 | TEL Address Address TEL Institute Organization Address2 Tel2 Institutions |
|
| 7 | Update | 2016/07/08 15:09:01 | Name of primary person or sponsor Organization |
|
| 8 | Update | 2017/09/06 09:08:18 | Last follow-up date |
|
| 9 | Update | 2018/08/23 17:36:32 | Public title |
|
| 10 | Update | 2018/08/24 10:04:27 | UMIN ID1 |
|
| 11 | Update | 2019/03/28 15:47:46 | Recruitment status Date of IRB Anticipated trial start date |
|
| 12 | Update | 2019/11/21 17:02:20 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Organization Organization Division name Division name Zip code Address Address Last name of contact person Last name of contact person Organization Zip code Address Homepage URL Institute Organization Organization Organization Address Address Tel |
|
| 13 | Update | 2021/08/18 10:12:32 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
